EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential

Bahareh Farasati Far, Marziyeh Akbari, Mohammad Amin Habibi, Morteza Katavand, Sherko Nasseri iD

Cell Proliferation · 2025-11 · 58 (11)

DOI: 10.1111/cpr.70099 ↗

At a glance

Journal article in Cell Proliferation, published online on 2025-07-20. Written by Bahareh Farasati Far and 4 co-authors. Institution: Research Laboratory of Green Organic Synthesis and Polymers, Department of Chemistry, Iran University of Science and Technology, Tehran, Iran. Major MEDLINE topics: CRISPR-Cas Systems, Translational Research, Biomedical. Cited 20 times so far (Crossref); 271 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

CRISPR‐Cas9 technology has rapidly advanced as a transformative genome‐editing platform, facilitating precise genetic modifications and expanding therapeutic opportunities across various diseases. This review explores recent developments and clinical translations of CRISPR applications in oncology, genetic and neurological disorders, infectious diseases, immunotherapy, diagnostics, and epigenome editing. CRISPR has notably progressed in oncology, where it enables the identification of novel cancer drivers, elucidation of resistance mechanisms, and improvement of immunotherapies through engineered T cells, including PD‐1 knockout CAR‐T cells. Clinical trials employing CRISPR‐edited cells are demonstrating promising results in hematologic malignancies and solid tumours. In genetic disorders, such as hemoglobinopathies and muscular dystrophies, CRISPR‐Cas9 alongside advanced editors like base and prime editors show significant potential for correcting pathogenic mutations. This potential was affirmed with the FDA's first approval of a CRISPR‐based therapy, Casgevy, for sickle cell disease in 2023. Neurological disorders, including Alzheimer's, ALS, and Huntington's disease, are increasingly targeted by CRISPR approaches for disease modelling and potential therapeutic intervention. In infectious diseases, CRISPR‐based diagnostics such as SHERLOCK and DETECTR provide rapid, sensitive nucleic acid detection, particularly valuable in pathogen outbreaks like SARS‐CoV‐2. Therapeutically, CRISPR systems target viral and bacterial genomes, offering novel treatment modalities. Additionally, CRISPR‐mediated epigenome editing enables precise regulation of gene expression, expanding therapeutic possibilities. Despite these advances, significant challenges remain, including off‐target effects, delivery methodologies, immune responses, and long‐term genomic safety concerns. Future improvements in editor precision, innovative delivery platforms, and enhanced safety assessments will be essential to fully integrate CRISPR‐based interventions into standard clinical practice, significantly advancing personalised medicine.

Subjects

MeSH terms (MEDLINE)

CRISPR-Cas SystemsTranslational Research, BiomedicalHumansAnimalsGene EditingGenetic EngineeringGenetic VariationCOVID-19SARS-CoV-2Immunotherapy

Author keywords

CRISPR‐Cas systemscancersepigenome editinggenetic therapyiPSCmolecular diagnostic techniquesnervous system diseasespersonalised medicine

Authors and institutions

  • Research Laboratory of Green Organic Synthesis and Polymers, Department of Chemistry, Iran University of Science and Technology, Tehran, Iran.
  • Department of Genetics, Faculty of Science, Shahrekord University, Shahrekord, Iran.
  • Gene, Cell & Tissue Research Institute, Tehran University of Medical Science, Tehran, Iran.
  • Clinical Research Development Center, Qom University of Medical Sciences, Qom, Iran.
  • Department of Genetics, Faculty of Basic Science, Islamic Azad University, Science and Research Branch, Tehran, Iran.
  • Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta, Georgia, USA.

ORCID profiles: Sherko Nasseri

Cite

APA

Far, B. F., Akbari, M., Habibi, M. A., Katavand, M., & Nasseri, S. (2025). CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential. Cell Proliferation, 58(11). https://doi.org/10.1111/cpr.70099

Vancouver

Far BF, Akbari M, Habibi MA, Katavand M, Nasseri S. CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential. Cell Proliferation. 2025;58(11). doi:10.1111/cpr.70099

BibTeX
@article{Far2025,
  author = {Far, Bahareh Farasati and Akbari, Marziyeh and Habibi, Mohammad Amin and Katavand, Morteza and Nasseri, Sherko},
  title = {CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential},
  journal = {Cell Proliferation},
  year = {2025},
  volume = {58},
  number = {11},
  doi = {10.1111/cpr.70099}
}
Start for free →